Pharmacotherapy of Insomnia

Area of Science:

• Pharmacology
• Sleep Medicine
• Public Health

Background:

• Insomnia is a prevalent clinical concern with significant negative daytime consequences and societal impact.
• Medication remains a primary treatment approach for insomnia.
• Regulatory agencies have categorized insomnia drugs into four distinct pharmacodynamic classes.

Purpose of the Study:

• To review the current landscape of insomnia pharmacotherapy.
• To highlight recent advances in hypnotic medication development.
• To emphasize the trend towards personalized treatment approaches in insomnia.

Main Methods:

• Review of pharmacodynamic classifications of insomnia medications.
• Analysis of approved hypnotic drug classes: benzodiazepine receptor agonists, melatonin receptor agonists, selective histamine receptor antagonists, and dual orexin/hypocretin receptor antagonists.
• Discussion of pharmacodynamic and pharmacokinetic advancements.

Main Results:

• Four main pharmacodynamic classes of insomnia medications are approved.
• Recent advances have expanded the range of available hypnotic medications.
• Personalized treatment is increasingly feasible due to expanded options.

Conclusions:

• Advances in pharmacodynamics and pharmacokinetics have broadened insomnia treatment options.
• The classification of insomnia medications facilitates tailored therapeutic strategies.
• Personalized medicine approaches can address varied patient populations and sleep patterns effectively.